secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2024-07-02T23:59:59+00:00
Accession:  0001558370-24-009650
Event type: m_and_a
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus licenses toripalimab rights in Canada to Apotex for $6.25M upfront
--------------------------------------------------------------------------

- Upfront payment of $6.25M USD; up to $51.5M CAD in regulatory and sales milestones.
- Apotex to pay low double-digit percentage of net sales; Coherus pays Junshi under existing collaboration.
- License term: 10 years after first commercial sale, with option to extend for another 10 years.
- Apotex may terminate for any reason after notice; agreement ends if Coherus-Junshi collaboration terminates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000155837024009650/0001558370-24-009650-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000155837024009650/chrs-20240627x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-009650

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer